Form 8-K STRATA Skin Sciences, For: Aug 03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 2, 2021
STRATA SKIN SCIENCES, INC.
(Exact Name of Registrant Specified in Charter)
Delaware
|
000-51481
|
13-3986004
|
(State or Other
|
(Commission File
|
(I.R.S. Employer
|
Jurisdiction of
|
Number)
|
Identification No.)
|
Incorporation)
|
|
|
|
5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania
|
19044
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
Registrant's telephone number, including area code: 215-619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
SSKN
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company. ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD
Disclosure.
On August 2, 2021, Strata Skin Sciences (the “Company”) announced the appointment of Brent Cowgill as Vice President of Marketing. Mr. Cowgill has over 20 years of healthcare sales and marketing
experience. Prior to joining the Company he managed Vantage Marketing, a healthcare consulting firm which he founded 9 years ago, that focused on commercializing prescription treatments in the U.S. market. Brent has held various commercial
positions at both Fortune 500 and emerging healthcare companies. His roles and responsibilities, while varied, stayed focused on supporting the strategic and commercial efforts at companies such as Graceway Pharmaceuticals, Bioglan Pharmaceuticals,
and Bristol Myers Squibb. Mr. Cowgill holds a B.S. degree in Marketing from Bowling Green State University.
The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall
be expressly set forth by specific reference in any such filing.
Item 9.01 Financial Statements
and Exhibits.
(d)
|
Exhibits:
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|
|
|
|
|
|
Date: August 3, 2021
|
By:
|
/s/ Matthew C. Hill
|
|
|
|
Matthew C. Hill
|
|
|
|
Chief Financial Officer
|
|
- 2 -
EXHIBIT 99.1
Strata Skin Sciences Announces Appointment of New VP of Marketing
Horsham, Pa., August 2, 2021 —
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the
appointment of Brent Cowgill as Vice President of Marketing.
“We are delighted to welcome Mr. Cowgill to the STRATA team,” said Robert J. Moccia, Chief Executive Officer of STRATA. “His extensive background in
healthcare sales and marketing will prove to be invaluable in the execution of our strategic marketing efforts to both customers and dermatologists. One of our highest priorities at STRATA is driving superior commercial execution and we believe
that Brent is the ideal leader to help us achieve and maintain this goal.”
Mr. Cowgill has over 20 years of healthcare sales and marketing experience. Prior to joining STRATA he managed Vantage Marketing, a healthcare consulting
firm which he founded 9 years ago, that focused on commercializing prescription treatments in the U.S. market. Brent has held various commercial positions at both Fortune 500 and emerging healthcare companies. His roles and responsibilities, while
varied, stayed focused on supporting the strategic and commercial efforts at companies such as Graceway Pharmaceuticals, Bioglan Pharmaceuticals, and Bristol Myers Squibb. Mr. Cowgill holds a B.S. degree in Marketing from Bowling Green State
University.
“I am very excited to join the STRATA team,” said Mr. Cowgill. “I look forward to helping STRATA expand its presence within the dermatology market while
building upon XTRAC's commercial success as the market’s leading excimer laser technology used to treat several chronic skin conditions that afflict millions of people worldwide.”
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the
treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic
dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and
insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
Investor Contact
Leigh Salvo
|
|
|
(415) 937-5404
|
|
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- STRATA Skin Sciences to Present at the Planet MicroCap Showcase: Vegas 2024
- Bitfarms Schedules First Quarter 2024 Conference Call on May 13, 2024
- Form 8.3 - ABRDN European Logistics
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!